Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

Lancet

Volumn 352, Issue 9133, 1998, Pages 1031-1032

  Henry, Keith ^a   Melroe, Holly ^b   Huebesch, Jacquelyn ^b   Hermundson, Jessica ^b   Simpson, Jane ^b  

^a REGIONS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GEMFIBROZIL; LIPID; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; EXERCISE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0032569488     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)00022-1     Document Type: Article

References (5)

1. 1 Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-58.
2. 2 Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenisis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998; 351: 1881-83.
3. 3 Henry K, Melroe H, Huebesch J, et al. Coronary artery disease associated with protease inhibitors. Lancet 1998; 351: 1328.
4. 4 Kovanen PT, Mantrari M, Palosuo T, et al. Prediction of myocardial infarction in dislipidemic men by elevated levels of immunoglobulin casses A, E, and F, but not M. Arch Intern Med 1998; 158: 1434-39.
5. 5 Danesh J, Collins R, Peto R. Chronic infections and coronary artery disease: is there a link? Lancet 1997; 350: 430-36.